Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > BUSINESS
BUSINESS
- Boehringer Exec Expects AMED’s Positive Impact on Company
November 18, 2015
- Japan Pharma Market Likely to Reach 9.7 Trillion Yen in 2022: Fuji Keizai
November 18, 2015
- Generic Makers’ Earnings Show Unabated Momentum 1 Year after Medical Fee Reform: Tally
November 17, 2015
- Otsuka Hopes Abilify Maintena Grabs 30% Share in Global Atypical Antipsychotic Market in 2018
November 17, 2015
- AZ Eyes Low Single-Digit Growth over Coming Years in Japan: Pres. Baertschi
November 16, 2015
- Bayer Yakuhin Now Marketing Authorization Holder for Claritin
November 16, 2015
- Taiho Files for Japan Approval of Allergy Drug Bilastine
November 16, 2015
- Senju, Gene Techno to Form Capital Tie-Up for Biosimilar Development in Ophthalmology
November 16, 2015
- NHI Prices of Plavix Generics “Actually 43% Rather than 50% Price of Original Product”: Sawai Pharmaceutical President
November 16, 2015
- Japanese Makers Earn Overseas in 1st Half, Japan Sales Up Only Slightly: Tally
November 13, 2015
- OrphanPacific Aims to Achieve Black Ink in 2017
November 13, 2015
- Astellas to Transfer Global Dermatology Portfolio to LEO Pharma
November 12, 2015
- Sovaldi Best-Selling Drug in July-September after May Launch: IMS
November 11, 2015
- Astellas to Acquire US Biotech Ocata Therapeutics for US$379 Million
November 11, 2015
- Top 4 Wholesalers See 7% Sales Rise on Hep C Drugs, but Paltry 0.82% in Operating Margin
November 11, 2015
- Chugai, Kowa Expand Licensing Deal for Deberza
November 11, 2015
- Ethical Dug Sales Climb 7.8% in September: Crecon Report
November 11, 2015
- Fujifilm’s AML Drug Candidate to Enter PI in US
November 11, 2015
- Shionogi, GSK to Independently Develop Jointly Researched Antibiotics
November 10, 2015
- Jardiance Jumps into Top 20 Ranking on Physicians’ Recollection: Anterio
November 10, 2015
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…